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Glucometers for Patients with Type 2 Diabetes Mellitus: Are 
they helpful? 
Andrew Thomas,1 Mohan T Shenoy,2 K.T. Shenoy,3 Nirmal George.4 
Abstract 
Background: The effectiveness of self-monitoring of blood glucose (SMBG) in type 2 diabetes mellitus (T2DM) patients is debated in the literature. We 
aimed at elucidating the association and patterns of complications between SMBG use and plasma glucose values. Methods: This cross-sectional study 
comprised 303 participants from outpatient departments with T2DM for over 12 months. We analyzed sociodemographic and clinical variables including: 
anthropometry, SMBG use, disease duration, treatment modality, complications, plasma glucose level, and glycated hemoglobin level (%). Results: The 
mean duration of T2DM was 93 ± 76 months. Participants were grouped into SMBG users (n=115, 38%) and non-SMBG users (n=188, 62%). The mean fasting 
plasma glucose levels of SMBG and non-SMBG users were 140.7±42.7 (95% Confidence Interval [95%CI]: 132.72;148.67) mg/dl and 145.4±50 (95%CI: 
138.12;152.67) mg/dl (p=0.03), respectively. The mean post-prandial plasma glucose levels of the SMBG and non-SMBG groups were 202 ± 63.42 (95%CI: 
190.23;213.76) mg/dl and 209±84.54 (95%CI: 196.56;221.43) mg/dl (p=0.002), respectively. The mean difference in HbA1c among the groups were 8.14±1.69% 
(95%CI: 7.59;8.68) and 8.15±1.98% (95%CI: 7.27;9.02) (p=0.4), respectively. Hypoglycemia (n=50, 43.5%) was the most common complication. The prevalence 
of neuropathy (n=5, 4.3%, p=0.036) and cardiovascular disease (n=21, 18.3%, p=0.042) were significantly higher in the SMBG group. Conclusion: Although 
plasma glucose values were significantly lower in the SMBG group, its clinical significance remains questionable. Furthermore, many participants in both 
groups had shortfalls in awareness, monitoring, and glycemic control. SMBG use needs to be evaluated in a cohort of patients with T2DM with adequate 
health awareness. 
 




India is a country with a high incidence of diabetes mellitus. The 
morbidity and mortality related to this disease are enormous and pose 
a significant burden on the public health of this country in the future.1 
Venous plasma and capillary whole blood methods are two ways of 
estimating blood glucose level. The venous plasma glucose level is 
slightly higher in random and fasting glucose estimation, but lower than 
capillary whole blood glucose level for samples taken 2 hours after 
glucose is given orally. However, the diagnostic criteria are similar 
between these two methods of estimation.2 According to the American 
Diabetic Association (ADA), random blood glucose values of 79–140 
mg/dl are considered normal; 140–200 mg/dl, pre-diabetes; and a value 
above 200 mg/dl, diabetes. In terms of glycated hemoglobin levels, 
values less than 6.5% are normal, whereas values between 5.7% and 
6.7% are considered high risk. 3, 4 Control of blood glucose is important 
in preventing diabetes-associated complications; however, over 70% of 
all patients diagnosed with diabetes have uncontrolled diabetes.5 
 
Some may argue that self-monitoring of blood glucose (SMBG) can be 
recommended for all patients with type 2 diabetes mellitus (T2DM).6 
This is because SMBG can be useful in detecting hypoglycemia and 
hyperglycemia. Furthermore, high blood glucose levels encourage 
patients to improve their diet and physical activity. Multiple SMBG 
measurements taken over a period of time may also be helpful for 
physicians to monitor their patients and modify their treatment if 
needed.6, 7 Glycemic variability is a term used to describe the 
fluctuations of glucose levels. While SMBG may provide diurnal glucose 
profile, continuous glucose monitoring (CCM) is considered helpful in 
detecting glycemic variability.8 
The data on SMBG practice among patients with T2DM are not well 
understood. Many studies have been conducted to estimate the 
effectiveness of SMBG practice, especially among non-insulin-treated 
patients. Some studies revealed no association between in SMBG and 
glycemic control, whereas others indicated the benefits of SMBG use.9–
14 A reduction in hemoglobin A1C (HbA1C) of 0.5% was found when the 
patients were better educated to interpret the values of SMBG.7 
Physicians need to monitor patients with T2DM regularly, because the 
effectiveness of SMBG is dependent both on patients and appropriate 
glucometer use.15 Patients should be made aware that practicing SMBG 
alone will not improve their glycemic control. Good glycemic control is 
attained only when data obtained are properly interpreted to modify 
treatment strategies. This study aimed at elucidating the use of SMBG 
in patients with T2DM by comparing glycemic levels and complication 
rates among SMBG and non-SMBG users. 
 
Methods 
This was a cross-sectional study conducted from May to June 2019. The 
project was approved by the Institutional Ethical Committee of Sree 
Gokulam Medical College and Research Foundation (SGMC-IEC no.: 
34/450/05/2019). Each participant provided a written informed consent 
before the commencement of the study. 
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Sree Gokulam Medical College and Research Foundation (SGMC&RF) is 
a tertiary health center located at Thiruvananthapuram in the state of 
Kerala, India. Study participants were selected by convenient sampling 
from the outpatient departments of General medicine, General Surgery, 
Orthopedics, Endocrinology, Diabetology, and Gastroenterology of 
SGMC&RF. Participants with T2DM for over 12 months and those aged 
at least 18 years were included in the study. Pregnant women were 
excluded from the study. 
 
Socio-demographics, anthropometry (height in cm and weight in Kg), 
duration of disease (in months), current treatment pattern [6 treatment 
modalities, namely insulin preparations, oral hypoglycemic drugs 
except metformin monotherapy, metformin monotherapy, alternative 
drug therapy like Ayurveda or Homeopathy, combination therapy 
(insulin and oral hypoglycemic drugs), and no treatment], recent 
plasma glucose values (fasting, post-prandial in mg/dl, and HbA1C as a 
percentage), co-morbidities, such as hypertension, dyslipidemia, hypo- 
and hyperthyroidism, bronchial asthma, cardiovascular disease (cardiac 
failure, arrhythmias, and myocardial infarction), stroke (both ischemic 
and hemorrhagic), neuropathy, nephropathy, and retinopathy, and 
pattern of SMBG use (duration, frequency) were the variables studied. 
 
Awareness and practice of SMBG among the study participants were 
enquired and noted. Following data collection, all participants were 
educated on disease progression and appropriate SMBG practice. 
 
Data were collected through interviews lasting 15 minutes conducted 
by the principal investigator, using questionnaires on SMBG practice. 
Height and weight were measured for calculating BMI. Laboratory 
records, such as blood glucose, lipid profile, and HbA1C, were perused 
from the electronic records database with patients’ permission. Only 
their most recent blood values were used in the study for analysis. All 
eligible and consenting participants were recruited to minimize the 
selection and sampling bias. 
 
The sample size was estimated based on a previous report15 using the 
Open-Epi (Open-Source Epidemiologic Statistics for Public Health)16 
software. A proportion of 52.4% was assumed to be SMBG users with a 
precision of 5%, alpha error (0.05), and power of 90%; the required 
sample size was calculated. All quantitative variables were compared 
using the mean and standard deviation. 
 
The association between SMBG practice and plasma glucose values was 
assessed using the independent t-test. Chi-square test and odds ratio 
with 95% Confidence Interval (95%CI) were used to determine the 
association between complications and SMBG practice. A sub-group 
analysis among the non-insulin-taking participants was performed to 
determine the association between SMBG use and glycemic values of 
non-insulin-taking participants. A p-value <0.05 was considered 
statistically significant. SPSS version 25 (Statistical Package for the 
Social Sciences, SPSS Inc., U.S.A) was used for all data analyses. 




Overall, 303 participants were interviewed in our study, of which 171 
(56.4%) were males and 132 (43.6%) were females. Age-wise, 141 
(46.5%) and 162 (53.5%) participants were above and below 60 years, 
respectively (p=0.191). The total population age average was 59.61 ± 
10.26 years. The mean duration of T2DM in our study sample was 93.5 
months. The BMI of 294 participants were assessed using the Asian BMI 
criteria17 (Table 1). Nine participants were excluded from this analysis 
due to missing information, after which 147 (50%), 64 (21.8%), 76 
(25.8%), and 7 (2.5%) participants were determined to be obese, 
overweight, normal (18.5 to 23 kg/m2), and underweight, respectively. 
No statistically significant difference in BMI was observed between 
SMBG and non-SMBG users (p=0.2). 
 
SMBG Practice 
The study participants were classified into SMBG (115, 38%) and non-
SMBG groups (188, 62%). Among the SMBG group, 96 (83.5%), 8 (7%), 5 
(4.3%), 4 (3.5%), and 2 (1.7%) participants practiced SMBG irregularly, once 
weekly, once monthly, once daily, and multiple times a day, respectively. 
 
Table 1. Participants Classified According Asian BMI Criteria 
 
Asian BMI criteria SMBG group Non-SMBG group 
Underweight (<18.5 kg/m2) 7 0 
Normal (18.5–23 kg/m2) 44 32 
Overweight (23.1–27.5 kg/m2) 37 27 
Obese (≥27.5 kg/m2) 92 55 
 
A summary of different treatment modalities administered to the study 
participants is given in Table 2. Metformin monotherapy administered 
to 113 (37.3%) participants was the most common treatment modality, 
whereas 51 (16.8%) and 63 (20.8%) participants were on insulin 
monotherapy and combined therapy with insulin and oral hypoglycemic 
drugs, respectively. Participants were grouped based on insulin use for 
sub-group analysis. No significant difference was observed between them. 
 
Table 2. Treatment Modalities Used by Study Participants for Control of Type 










Metformin 30 (26.1%) 83 (44.1%) 0.002⸸ 
Monotherapy with oral anti-
diabetic drugs (except 
metformin) 
13 (11.3%) 20 (10.6%) 0.86⸸ 
Combination of more than 
one oral anti-diabetic drugs  
7 (6.1%) 11 (5.9%) 0.93⸸ 
Insulin Preparations 23 (20%) 28 (14.9%) 0.25⸸ 
Insulin and oral anti-diabetic 
drugs 
32 (27.8%) 31 (16.5%) 0.02⸸ 
Alternative medicine* 3 (2.6%) 1 (0.5%) 0.15‡ 
No medications 7 (6.1%) 14 (7.4%) 0.65⸸ 
 
Legend: * Alternative medicine includes Ayurveda, Siddha, Unani, and Homeopathy 
treatments. ⸸ Chi2, ‡ Fisher’s exact test 
 
Most of the participants (79, 68.7%) performed SMBG after overnight 
fasting, whereas 3 (2.6%) and 33 (28.7%) participants performed it 2 
hours after eating and randomly, respectively. More than half (74, 
64.3%) of the participants felt they were not adequately educated about 
SMBG use. Among the SMBG users, only 38 (33%) participants modified 
their treatment using SMBG values. The other 78 (67.8%) participants 
began exercising and had diet modifications because of SMBG use. 
 
In all, 60 (52.2%) participants said they would verify the SMBG values 
by performing follow-up tests in certified laboratories. However, 48 
(41.7%) participants did not confirm their SMBG values at any 
laboratories. Only 7 (6.1%) participants consulted physicians on their 
SMBG values. 
 
SMBG Use and Glycemic Levels 
The mean plasma glucose and HbA1c levels of the SMBG and non-SMBG 
groups were compared using t-test (Figure 1). The fasting plasma 
glucose levels of 297 participants were analyzed. Among them, 113 
participants practiced SMBG. The mean plasma fasting glucose levels 
were 140.47±42.7 (95%CI: 132.72–148.67) mg/dl and 145.4±50 (95%CI: 
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Figure 1. Association between glycemic levels and SMBG use. (A) Mean fasting and Post-prandial plasma glucose between SMBG and Non-SMBG groups. 





Table 3. Frequency of complications and co-morbidities observed in study participants 
 
Complications and Co-morbidities Total (n=303) SMBG group (n=115) Non- SMBG group (n=188) P value 
Retinopathy 54 (17.8%) 25 (21.7%) 29 (15.4%) 0.16 
Nephropathy 10 (3.3%) 5 (4.3%) 5 (2.7%) 0.42 
Neuropathy 20 (6.6%) 12 (10.4%) 8 (4.3%) 0.04 
Hypoglycemia 117 (38.6%) 50 (43.5%) 67 (35.6%) 0.17 
Cardiovascular disease 40 (13.2%) 21 (18.3%) 19 (10.1%) 0.04 
Stroke 8 (2.6%) 4 (3.5%) 4 (2.1%) 0.48 
Hypertension 151 (49.8%) 49 (42.6%) 102 (54.3%) 0.04 
Dyslipidemia 141 (46.5%) 51 (44.3%) 90 (47.9%) 0.55 
Thyroid dysfunction 45 (14.9%) 15 (13%) 30 (16%) 0.49 
 
 
prandial (7 mg/dl, p=0.002) plasma glucose. HbA1c levels of the SMBG 
and non-SMBG groups were 8.14%±1.69 (95%CI: 7.59-8.68) and 
8.15%±1.98 (95%CI: 7.27-9.02), respectively. However, no significant 
difference was observed in the mean HbA1c levels between both 
groups. A sub-group analysis with t-test was conducted for the non-
insulin users. No statistically significant difference was identified 
between both groups, in terms of their fasting (p=0.4, t=-0.8), post-
prandial (p=0.9, t=0.1), or HbA1c levels (p=0.7, t=0.3). 
 
Complication Comparison Between SMBG and Non-SMBG Participants 
Table 3 summarizes the pattern of complications and co-morbidities. 
Out of the 303 participants, 117 (38%) had hypoglycemia, which was 
the most common complication (p=0.17). Fifty-nine (19.5%) participants 
had at least one micro-vascular (retinopathy, nephropathy, and 
neuropathy) complication, and 45 (14.8%) participants had at least one 
macro-vascular (cardiovascular diseases and stroke) complication. 
 
More participants who practiced SMBG had neuropathy (n=12, 10.4%, 
p=0.03) and cardiovascular disease (n=21, 18.3%, 0.04). The odds ratios 
(OR) of micro-vascular (OR=1.8, 95%CI=1.00–3.2) and macro-vascular 
complications (OR=2.1, 95%CI=1.1–3.9) were significantly different when 
analyzing SMBG and non-SMBG groups, as summarized in Figure 2. 
Micro-vascular and macro-vascular complications were prevalent in 
both the non-SMBG and SMBG groups. 
 
Discussion 
The usefulness of SMBG practice among patients with T2DM, especially 
those without insulin medication, is doubtful in the literature. We 
conducted a cross-sectional study among 303 patients with T2DM 
patients with and without SMBG practice, and compared their fasting, 
post-prandial and HbA1c values. The mean HbA1c values did not differ 
between the two groups. While the mean plasma glucose values 
between the groups may be statistically significant, the differences 
were too infinitesimal to produce a clinically significant difference. A 
mere 7 mg/dl difference in post-prandial glucose is doubtful to elicit a 
clinically significant difference in practice.18 
 
One of the specific goals for practicing SMBG is to detect and prevent 
hypoglycemia.20 Contrary to this, hypoglycemia was the most common 
complication observed in the participants. Furthermore, no statistically 
significant difference existed in the proportion of hypoglycemia 
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Figure 2. Frequency of micro-vascular and macro-vascular complications 
among SMBG and non-SMBG users. (a) denotes odds ratio 1.8, 95%Cl 




Most of the complications, except neuropathy and cardiovascular 
disease, had no statistically significant differences between the two 
groups. The leading cause of mortality and morbidity in patients with 
diabetes is related to cardiovascular events.22 A weak, yet significant 
association between SMBG use and cardiovascular disease has been 
reported.23 Huang et al. 24 observed that frequent SMBG monitoring 
decreased micro-vascular complications. One interesting finding was 
that neuropathy and cardiovascular diseases were more prevalent in 
the SMBG group with statistical significance. Overall, our study observed 
that more micro-vascular complications were present in the non-SMBG 
group (29 vs. 30), whereas more macro-vascular complications were 
present in the SMBG group (24 vs. 21). However, these complications 
may not be associated with SMBG use. A possible explanation for this 
finding might be that participants with more complications used SMBG 
because of severe disease. 
 
SMBG use in T2DM is debated in the literature. Improvement in glycemic 
control can only be found if the patient is educated about the 
appropriate ways of practicing SMBG.25, 26 Many patients in our study 
were not satisfied with the health education they received from the 
healthcare provider. Most patients practiced SMBG irregularly and did 
not confirm or consult physicians on results. This might be the reason 
for poor response to SMBG practice in our study setting. Perhaps, the 
most concerning finding in our study was that mean fasting, post-
prandial, and HbA1C of both groups were significantly higher than the 
recommended glycemic targets by American Diabetes Association 
(ADA), American College of Endocrinologists, and International Diabetes 
Federation (IDF).19 In India, education on diabetes is not enough to 
impart adequate awareness and monitoring status of glycemic 
control.27 Thus, determining the efficiency of SMBG is challenging. 
 
The effectiveness of SMBG especially among patients with T2DM who 
are not on insulin therapy is debated in the literature. A systematic 
review and meta-analysis conducted in 2012 included 12 randomized 
controlled trials. They concluded that the effect of SMBG lasted only 
about six months in these patients. Furthermore, they also observed 
that the effectiveness decreases after one year.28 Another multicenter 
analysis on 24,500 patients from 191 centers observed that patients 
with T2DM on oral hypoglycemic agents or nutrition therapy derived no 
apparent benefits from SMBG.29 These findings are similar to those of 
our study. One prospective study conducted among 689 patients 
observed benefits in patients who performed SMBG, but observed a 
0.3% reduction in HbA1c level (8.1 ± 1.6% vs. 8.4 ± 1.4%, p = 0.012). 
Thus, any claims of significant clinical effects of SMBG among SMBG 
users are doubtful.13 
 
The study had few limitations. First, information bias due to reliance 
on self-declared information was most likely. Second, ideally, a 
randomized controlled trial would be better to ascertain the differences 
between the SMBG and non-SMBG groups. Third, while we only included 
participants who practiced SMBG for at least 6 months, we did not 
analyze the duration of SMBG use with their glycemic values. 
 
Even though our study indicated a significant difference in fasting and 
post-prandial plasma glucose, participants had shortfalls in awareness, 
practice, and control of diabetes. Further studies using randomized 
controlled trials and meta-analysis should be conducted on patients 
with T2DM using SMBG to determine its effectiveness and establish 
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